|
Federal judge temporarily blocks Trump administration freeze on federal grants and loans
A federal judge on Tuesday temporarily blocked a push from President Donald Trump to pause federal funding while his administration conducts an across-the-board ideological review to uproot progressive initiatives.
'No new studies are being launched': NIH explains the impact of Trump administration’s freeze | Fierce Biotech
Just days after President Trump imposed broad restrictions on communications, meetings, travel and public appearances at the Department of Health and Human Services (HHS), the National Institutes of Health (NIH) is clarifying the extent of the freeze’s effect.
Philips to sell emergency care business | MedTechDive
Investment firm Bridgefield Capital will buy the segment, which includes cardiac resuscitation and emergency care devices, for an undisclosed amount.
Researchers reel as Trump administration moves quickly to cut funding and end DEI health programs | STAT
‘The work is hard enough to do as it is,’ said one advocate who urged scientists to push back
How Might the FDA Evolve Under RFK Jr. and Makary? | BioSpace
Ahead of Robert F. Kennedy Jr.’s confirmation hearings, experts—and RFK’s own family—expressed concerns about his vaccine-related views, though the same experts are largely unfazed by the level of power he and Marty Makary could ultimately wield over the FDA.
Stryker will sell spine implant business; CFO set to retire | MassDevice
Stryker today announced a deal to sell its U.S. spine implants business to investment firm Viscogliosi Brothers, which will call the new company VB Spine.
Trump freezes federal grants, with potentially large impact on providers, Medicaid
| BioPharmaDive
Trump’s budget office ordered all federal agencies to pause financial assistance, including grants, pending a review of their programs.
FDA approves Novo Nordisk’s Ozempic to treat chronic kidney disease in those with diabetes, expanding its use | CNBC
The Food and Drug Administration approved Novo Nordisk’s Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S.
Why are there only 20 cell and gene therapies in Europe? | Labiotech
In 2020, we wrote about why there were only 11 cell and gene therapies in Europe. A bit over four years later, there are 20 – almost twice as many. But is it such a big improvement? Take a look overseas, the U.S. market currently counts 43.
Zimmer Biomet to buy Paragon 28 for $1.1 billion | Reuters
Zimmer Biomet said on Tuesday it would acquire medical device company Paragon 28 for about $1.1 billion to expand its portfolio of orthopedic surgical devices.
| 
